Vitravene (fomivirsen)
CMV-induced retinitis
ApprovedFirst antisense drug approved
Key Facts
Indication
CMV-induced retinitis
Phase
Approved
Status
First antisense drug approved
Company
About Ionis Pharmaceuticals
Founded in 1989 by Stanley T. Crooke, Ionis Pharmaceuticals is a pioneer in RNA therapeutics with over three decades of innovation in antisense oligonucleotide technology. The company has successfully transitioned to a fully integrated biotechnology organization, launching its first independent medicine TRYNGOLZA (olezarsen) for familial chylomicronemia syndrome. With six currently marketed medicines discovered and developed by Ionis, the company maintains a rich late-stage pipeline focused primarily on neurology and cardiology, while continuing to advance breakthrough RNA-targeted therapies that have redefined treatment for serious genetic diseases.
View full company profile